Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PGD | P52209 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30571389 | 1.00 | TSHR (0.41) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL5359328 | 1.00 | TSHR (0.41) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL8891068 | 0.81 | TSHR (0.42) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL9842007 | 0.79 | TSHR (0.48) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL10753326 | 0.78 | TSHR (0.48) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL19604364 | 0.78 | TSHR (0.48) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL19359821 | 0.78 | ALDH1A1 (0.44) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL4951957 | 0.73 | TSHR (0.42) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL20865468 | 0.73 | TSHR (0.42) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL6789651 | 0.73 | TSHR (0.48) | TSHRCHRM2CHRM4CHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176229-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1242400-B1 | PYRROLIDINE DERIVATIVES AS CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORP (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20060074123-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-04-06 | — | — | US | disclosed |
| US-6998416-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2006-02-14 | — | — | US | disclosed |
| US-20040152754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (A WASHINGTON CORPORATION) | 2004-08-05 | — | — | US | disclosed |
| US-6716871-B2 | OBESITY; INFLAMMATORY DISEASES, DISEASES INVOLVING ELEVATED LEVELS OF CYTOKINES, CENTRAL NERVOUS SYSTEM DISORDERS; 3-HYDROXYALKYL-4-DIALKOXYPHENYL-SUBSTITUTED PYRROLIDINES | ICOS CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040023945-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1242400-A1 | PYRROLIDINE DERIVATIVES AS CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6423710-B1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2002-07-23 | — | — | US | disclosed |
| WO-2001047905-A1 | PYRROLIDINE DERIVATIVES AS CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023945-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE7A | TSHR 2900/4885CHRM2 1497/4885CHRM4 829/4885 |
| US-20040152754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | TSHR 2900/4885CHRM2 1497/4885CHRM4 829/4885 |
| US-20060074123-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE7A | TSHR 2900/4885CHRM2 1497/4885CHRM4 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.